Health Economics›Acute myeloid leukemia›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

Acute myeloid leukemia · 20 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Gemtuzumab ozogamicin monotherapy Variant #04	—	R 122 454	8d	—	~4.9 mo	—	—	1
Midostaurin monotherapy Variant #01	FLT3	R 76 418	28d	—	—	—	—	—
CLAG-M Variant #01	—	R 51 437	6d	—	—	—	—	—
CLAG Variant #01	—	R 40 978	—	—	—	—	—	—
F-SHAI Variant #01	—	R 35 570	11d	—	—	—	—	—
FLAG-Ida Variant #01	—	R 35 219	28d	—	5.4 mo	—	—	3
High-dose Cytarabine monotherapy (HiDAC) Variant #01	—	R 26 364	—	—	~60.0 mo	—	—	—
SHAI Variant #01	—	R 24 347	11d	—	—	—	—	—
IAP Variant #01	—	R 22 416	8d	—	—	—	—	—
FLAG Variant #01	—	R 21 352	—	—	~6.7 mo	—	—	1
MEC Variant #01	—	R 19 351	28d	—	5.4 mo	—	—	3
HAM Variant #01	—	R 13 754	—	—	—	—	—	—
MAC Variant #01	—	R 13 110	6d	—	—	—	—	—
ADE (standard-dose Ara-C) Variant #07	—	R 11 856	10d	—	—	—	—	1
Etoposide and Mitoxantrone Variant #01	—	R 11 505	—	—	—	—	—	—
5+2d Variant #01	—	R 5 983	5d	—	—	—	—	—
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01	—	R 3 662	28d	—	7.6 mo	—	—	1
CLARA Variant #01 Partial	—	R 3 662	35d	—	—	—	—	—
Cytarabine and Vosaroxin Variant #01 Partial	—	R 3 662	28d	—	~7.5 mo	—	—	1
Clofarabine and Cytarabine N/A - secondary systemic drug	—	R 0	28d	—	6.6 mo	—	—	1

20 of 20 regimens shown